The invention relates to the technical field of
medicinal chemistry, in particular to application of
hovenia acerba total triterpenes to preparation of a
medicine with a non-
small cell lung cancer resisting effect. Researches show that the
hovenia acerba total triterpenes have the effects of resisting NSCLC and enhancing sensitivity; the
hovenia acerba total triterpenes can inhibit A549
cell proliferation, migration and
apoptosis in a
dose-
dependent manner, and can stimulate the formation of
autophagosome and induce an
autophagy process, which indicates that the
hovenia acerba total triterpenes have the effect of KNSCLC. The
hovenia acerba total triterpenes can inhibit the activity of ARE-Leu
luciferase and increase the
cytotoxicity of the
hovenia acerba total triterpenes combined with
cisplatin, and the hovenia acerba total triterpenes combined with
cisplatin can significantly reduce the
protein expression of the Nrf2 pathway, which shows that the hovenia acerba total triterpenes have the effect of enhancing the sensitivity of NSCLC
drug-resistant cells. Therefore, the hovenia acerba total triterpenes used as the
active ingredient for preparing the
medicine with the anti-NSCLC effect have important application value.